Downregulation of glutathione transferase π sensitizes lymphoma/leukaemia cells to platinum-based chemotherapy

British Journal of Haematology

Volumn 162, Issue 1, 2013, Pages 135-137

  Chen, Jianli ^a,b   Hurford, Matthew ^b   Mekan, Sabeen ^b,c   Simpkins, Henry ^a,b  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

^c North Shore Long Island Center for Advanced Medicine   (United States)

Author keywords

Glutathione s transferase ; Lymphoma; Platinum resistance

Indexed keywords

CISPLATIN; DOXORUBICIN; GLUTATHIONE TRANSFERASE P1; OXALIPLATIN;

CANCER RESISTANCE; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME REGULATION; IC 50; LETTER; LEUKEMIA CELL; LYMPHOMA CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE TRANSFERASE; HUMANS; LEUKEMIA; LYMPHOMA; PLATINUM;

EID: 84879110262     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12324     Document Type: Letter

References (10)

1. Chau, I., Webb, A., Cunningham, D., Hill, M., Rao, S., Ageli, S., Norman, A., Gill, K., Howard, A. & Catovsky, D. (2001) An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. British Journal of Haematology, 115, 786-792.
2. Chen, J., Adikari, M., Pallai, R., Pallai, H.K. & Simpkins, H. (2008) Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells. Cancer Chemotherapy and Pharmacology, 61, 979-987.
3. Jian, H.V. & Meyer-Hermann, M. (2010) The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas. Cancer Research, 71, 705-715.
4. Oki, Y., McLaughlin, P., Pro, B., Hagemeister, F.B., Bleyer, A., Loyer, E. & Younes, A. (2005) Phase II study of oxaliplatin in patients with recurrent or refractory non-hodgkin lymphoma. Cancer, 104, 781-787.
5. Petrini, M., DiSimone, D., Favati, A., Mattii, L., Valenti, P. & Grassi, B. (1995) GST-π and P-170 co-expression in multiple myeloma. British Journal of Haematology, 90, 393-397.
6. Raderer, M., Wohrer, S., Bartsch, R., Prager, G., Drach, J., Hejna, M., Gaiger, A., Turetschek, K., Jaeger, U., Streubel, B. & Zielinski, C.C. (2005) Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. Journal of Clinical Oncology, 23, 8442-8446.
7. Ribrag, V., Koscielny, S., Carpiuc, I., Cebotaru, C., Vande Walle, H., Talbot, M., Fenaux, P. & Bosq, J. (2003) Prognostic value of GST-π expression in diffuse large B-cell lymphomas. Leukemia, 17, 972-977.
8. Thieblemont, C., Rolland, D., Baseggio, L., Felman, P., Gazzo, S., Callet-Bauchu, E., Traverse-Glehen, A., Houlgatte, R., Fu, K., Weisenburger, D., De Jong, D., Jaffe, E.S., Rosenwald, A., Ott, G., Coiffier, B. & Berger, F. (2008) Comprehensive analysis of GST-π expression in B-cell lymphomas: correlation with histological subtypes and survival. Leukemia and Lymphoma, 49, 1403-1406.
9. Townsend, D.M. & Tew, K.D. (2003) The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene, 22, 7369-7375.
10. Turella, P., Cerella, C., Filomeni, G., Bullo, A., De Maria, F., Ghibelli, L., Ciriolo, M.R., Cianfriglia, M., Mattei, M., Federici, G., Ricci, G. & Caccuri, A.M. (2005) Proapoptotic activity of new glutathione S-transferase inhibitors. Cancer Research, 65, 3751-3761.